Sigrun Hallmeyer
Experienced in Breast Cancer in Men

Dr. Sigrun Hallmeyer

Hematology | Oncology
Aurora Healthcare
Advocate Lutheran General Cancer Institute
1700 Luther Ln 1st & 2nd Fl, 
Park Ridge, IL 
On Staff At
Offers Telehealth

Experienced in Breast Cancer in Men
Aurora Healthcare
Advocate Lutheran General Cancer Institute
1700 Luther Ln 1st & 2nd Fl, 
Park Ridge, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sigrun Hallmeyer is a Hematologist and an Oncologist in Park Ridge, Illinois. Dr. Hallmeyer is rated as an Experienced provider by MediFind in the treatment of Breast Cancer in Men. Her top areas of expertise are Breast Cancer, Melanoma, Paget Disease of the Breast, and Angiosarcoma.

Her clinical research consists of co-authoring 21 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Pinnacle Health Hospitals, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine
Fellowships
University of Illinois College of Medicine at Chicago, Hematology/Oncology
Hospital Affiliations
Advocate Lutheran General Hospital
Advocate Sherman Hospital
Advocate Illinois Masonic Medical Center
Advocate Good Samaritan Hospital
Advocate Good Shepherd Hospital
Languages Spoken
English
German
Russian
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Advocate Lutheran General Cancer Institute
1700 Luther Ln 1st & 2nd Fl, Park Ridge, IL 60068
Call: 847-268-8200

Additional Areas of Focus

Dr. Hallmeyer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Ipilimumab
Study Phase: Phase 2
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
The Prevalence of SARS-CoV-2 IgG Antibody Formation in Physicians at Advocate Lutheran General Hospital and Their Household Members
The Prevalence of SARS-CoV-2 IgG Antibody Formation in Physicians at Advocate Lutheran General Hospital and Their Household Members
Enrollment Status: Completed
Publish Date: October 03, 2024
Intervention Type: Other
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Enrollment Status: Completed
Publish Date: June 03, 2024
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: April 13, 2021
Intervention Type: Drug
Study Phase: Phase 1
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
View 13 Less Clinical Trials

21 Total Publications

Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.
Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 13, 2024
View All 21 Publications
Similar Doctors
Malik T. Bandealy
Advanced in Breast Cancer in Men
Dr. Malik T. Bandealy
Hematology | Oncology
Advanced in Breast Cancer in Men
Dr. Malik T. Bandealy
Hematology | Oncology

Vince Lombardi Cancer Clinic

6811 118th Ave, 
Kenosha, WI 
 (28.8 miles away)
262-857-5750
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Offers Telehealth

Malik Bandealy is a Hematologist and an Oncologist in Kenosha, Wisconsin. Dr. Bandealy is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer in Men. His top areas of expertise are Angiosarcoma, Paget Disease of the Breast, Thrombocytopenia, and Adult Immune Thrombocytopenia.

Distinguished in Breast Cancer in Men
Dr. Shahid Shekhani
Oncology | Hematology
Distinguished in Breast Cancer in Men
Dr. Shahid Shekhani
Oncology | Hematology

Mercy Health System Corporation

N2950 State Rd, Suite 67, 
Lake Geneva, WI 
 (42.4 miles away)
262-245-0535
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances

Shahid Shekhani is an Oncologist and a Hematologist in Lake Geneva, Wisconsin. Dr. Shekhani is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer in Men. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Lynch Syndrome, and Colorectal Cancer.

Teresa Law
Distinguished in Breast Cancer in Men
Dr. Teresa Law
Oncology
Distinguished in Breast Cancer in Men
Dr. Teresa Law
Oncology

Endeavor Health Medical Group

757 Park Ave. West, Kellogg Cancer Center, 
Highland Park, IL 
 (8.1 miles away)
847-480-3800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Teresa Law, MD, a breast medical oncologist at Endeavor Health, provides comprehensive, evidence-based care for individuals navigating a breast cancer diagnosis. She combines clinical expertise with emotional support to treat the whole person—addressing physical, emotional and medical needs. Influenced by both her early oncology experience and her mother’s cancer diagnosis, Dr. Law is committed to ensuring patients feel informed, supported and well cared for throughout their journey. Dr. Law is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer in Men. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

VIEW MORE BREAST CANCER IN MEN DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hallmeyer's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Hallmeyer is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Hallmeyer is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Melanoma
      Dr. Hallmeyer is
      Distinguished
      . Learn about Melanoma.
      See more Melanoma experts
    • Paget Disease of the Breast
      Dr. Hallmeyer is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Advanced
    • Inflammatory Breast Cancer
      Dr. Hallmeyer is
      Advanced
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Melanoma of the Eye
      Dr. Hallmeyer is
      Advanced
      . Learn about Melanoma of the Eye.
      See more Melanoma of the Eye experts
    • Pleuropulmonary Blastoma
      Dr. Hallmeyer is
      Advanced
      . Learn about Pleuropulmonary Blastoma.
      See more Pleuropulmonary Blastoma experts
    • Experienced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Hallmeyer is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Hallmeyer is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Hallmeyer is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Agranulocytosis
      Dr. Hallmeyer is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Appendix Cancer
      Dr. Hallmeyer is
      Experienced
      . Learn about Appendix Cancer.
      See more Appendix Cancer experts
    • Bone Tumor
      Dr. Hallmeyer is
      Experienced
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.